NZ229700A - Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments - Google Patents
Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragmentsInfo
- Publication number
- NZ229700A NZ229700A NZ229700A NZ22970089A NZ229700A NZ 229700 A NZ229700 A NZ 229700A NZ 229700 A NZ229700 A NZ 229700A NZ 22970089 A NZ22970089 A NZ 22970089A NZ 229700 A NZ229700 A NZ 229700A
- Authority
- NZ
- New Zealand
- Prior art keywords
- complexes
- conjugates
- antibody
- radionuclides
- linker
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21149688A | 1988-06-24 | 1988-06-24 | |
US37095689A | 1989-06-21 | 1989-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ229700A true NZ229700A (en) | 1993-01-27 |
Family
ID=26906194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ229700A NZ229700A (en) | 1988-06-24 | 1989-06-23 | Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments |
Country Status (20)
Country | Link |
---|---|
US (1) | US5435990A (fr) |
EP (2) | EP0353450B1 (fr) |
JP (1) | JP2831073B2 (fr) |
KR (1) | KR0137930B1 (fr) |
AT (1) | ATE120457T1 (fr) |
AU (1) | AU634167B2 (fr) |
BR (1) | BR8907507A (fr) |
CA (1) | CA1341373C (fr) |
DE (2) | DE353450T1 (fr) |
DK (1) | DK175393B1 (fr) |
ES (1) | ES2013978A4 (fr) |
FI (2) | FI103792B1 (fr) |
GR (1) | GR900300034T1 (fr) |
HK (1) | HK60696A (fr) |
HU (1) | HU219485B (fr) |
IE (1) | IE67273B1 (fr) |
IL (1) | IL90730A0 (fr) |
NO (1) | NO179008C (fr) |
NZ (1) | NZ229700A (fr) |
WO (1) | WO1989012631A1 (fr) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422096A (en) * | 1985-05-08 | 1995-06-06 | The General Hospital Corporation | Hydroxy-aryl metal chelates for diagnostic NMR imaging |
US5250285A (en) * | 1985-05-08 | 1993-10-05 | The General Hospital Corporation | Hydroxy-aryl metal chelates for diagnostic NMR imaging |
EP0430968B1 (fr) * | 1988-05-02 | 1996-11-20 | PHANOS TECHNOLOGIES, Inc. | Composes, compositions et procede de liaison de substances de bio-affection sur des membranes superficielles de bio-particules |
US5756065A (en) * | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
JP2930708B2 (ja) * | 1988-12-23 | 1999-08-03 | ザ ダウ ケミカル カンパニー | イソチオシアナト官能化金属錯体の製造方法 |
US5914095A (en) * | 1989-04-07 | 1999-06-22 | Salutar, Inc. | Polychelants containg amide bonds |
US5686410A (en) * | 1989-07-20 | 1997-11-11 | Novartis Ag | Polypeptide derivatives |
JPH05503072A (ja) * | 1989-08-28 | 1993-05-27 | ザ・ゼネラル・ホスピタル・コーポレーション | 診断用nmr映像化の為のヒドロキシ―アリール金属キレート |
DE3938992A1 (de) * | 1989-11-21 | 1991-05-23 | Schering Ag | Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
US5410043A (en) * | 1991-12-06 | 1995-04-25 | Schering Aktiengesellschaft | Process for the production of mono-N-substituted tetraaza macrocycles |
KR930019648A (ko) * | 1992-03-27 | 1993-10-18 | 도키 가츠유키 | 테트라아자시클로도덴칸 유도체 및 그의 용도 |
WO1993020852A2 (fr) * | 1992-04-13 | 1993-10-28 | The Dow Chemical Company | Agents de chelation macrocycliques, leurs chelates et conjugues |
US5310535A (en) * | 1992-04-24 | 1994-05-10 | The Dow Chemical Company | Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies |
DE4218744C2 (de) * | 1992-06-04 | 1997-11-06 | Schering Ag | Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe |
US5505931A (en) * | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
US5462725A (en) * | 1993-05-06 | 1995-10-31 | The Dow Chemical Company | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
ES2156143T3 (es) * | 1993-12-30 | 2001-06-16 | Guerbet Sa | Ligandos poliaminados, complejos metalicos, procedimiento de preparacion, aplicaciones diagnosticas y terapeuticas. |
CA2180662A1 (fr) * | 1994-01-07 | 1995-07-13 | Ramaswamy Subramanian | Nouveaux chelateurs de polyaminocarboxylate |
WO1995026206A1 (fr) * | 1994-03-28 | 1995-10-05 | The Regents Of The University Of California | Procede d'elaboration de complexes agent de chelation-ligand etiquetes par radionucleide |
US5582814A (en) * | 1994-04-15 | 1996-12-10 | Metasyn, Inc. | 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging |
US6693190B1 (en) | 1994-05-11 | 2004-02-17 | Bracco International B.V. | Enhanced relaxivity monomeric and multimeric compounds |
EP0783326B1 (fr) * | 1994-09-07 | 2004-02-04 | The Dow Chemical Company | Procede de preparation d'agents chelateurs macrocycliques et formation de chelates et leurs conjugues |
US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
TW319763B (fr) | 1995-02-01 | 1997-11-11 | Epix Medical Inc | |
DE19505960A1 (de) * | 1995-02-21 | 1996-08-22 | Deutsches Krebsforsch | Konjugat zur individuellen Dosierung von Arzneimitteln |
TR28540A (tr) * | 1995-03-16 | 1996-09-30 | Guerbet Sa | Poliamine edilmis baglayicilar ve bunlarin metal kompleksleri. |
CN1203899C (zh) * | 1995-06-26 | 2005-06-01 | 螯合剂有限公司 | 对第一过渡系元素具有螯合亲和力和选择性的化合物及它们在医学冶疗中的用途 |
US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
AU2788099A (en) * | 1998-02-25 | 1999-09-15 | Biotraces, Inc. | Phosphate-based dendrimers for bioassays |
US6231832B1 (en) | 1998-03-23 | 2001-05-15 | Brookhaven Science Associates | Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use |
US6040124A (en) * | 1998-11-20 | 2000-03-21 | Eastman Kodak Company | Imaging element with biaxially oriented sheet with fluoropolymer |
EP2357192A1 (fr) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Endokine alpha humain et methodes d'utilisation |
US6696551B1 (en) * | 1999-03-23 | 2004-02-24 | The United States Of America As Represented By The Department Of Health And Human Services | 225Ac-HEHA and related compounds, methods of synthesis and methods of use |
LU90544B1 (en) * | 2000-03-14 | 2001-09-17 | Europ Economic Community | Bifunctional chelating agent |
AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2001282856A1 (en) | 2000-06-15 | 2001-12-24 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
KR20060088905A (ko) | 2000-06-16 | 2006-08-07 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 면역특이적으로 BLyS에 결합하는 항체 |
CA2436092A1 (fr) * | 2001-01-29 | 2002-08-08 | Idec Pharmaceutical Corporation | Anticorps modifies et procedes d'utilisation |
US7319139B2 (en) * | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
US6670456B2 (en) * | 2001-02-28 | 2003-12-30 | Dow Global Technologies Inc. | Actinium-225 complexes and conjugates for targeted radiotherapy |
CN100594935C (zh) | 2001-05-25 | 2010-03-24 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
DE10135356C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
EP2990417A1 (fr) | 2001-12-21 | 2016-03-02 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine et insuline |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
AU2003218456A1 (en) * | 2002-04-01 | 2003-10-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
AU2003226065B2 (en) | 2002-04-12 | 2009-02-26 | Ludwig Institute For Cancer Research, Ltd | Recombinant anti-interleukin-9 antibodies |
EP2070949B1 (fr) * | 2002-06-10 | 2013-01-16 | Vaccinex, Inc. | Anticorps anti-C35 et leur application pour le traitement du cancer |
US20030086868A1 (en) * | 2002-08-12 | 2003-05-08 | Dangshe Ma | Actinium-225 complexes and conjugates for radioimmunotherapy |
US7214545B2 (en) * | 2003-04-28 | 2007-05-08 | The Regents Of The University Of California | Element-coded affinity tags |
US8038983B2 (en) * | 2003-07-29 | 2011-10-18 | Immunomedics, Inc. | Fluorinated carbohydrate conjugates |
US20050079131A1 (en) * | 2003-08-08 | 2005-04-14 | Lanza Gregory M. | Emulsion particles for imaging and therapy and methods of use thereof |
JP4912153B2 (ja) | 2003-12-01 | 2012-04-11 | イミューノメディクス、インコーポレイテッド | タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法 |
WO2005055936A2 (fr) * | 2003-12-04 | 2005-06-23 | Vaccinex, Inc. | Procedes d'elimination de cellules tumorales par ciblage d'antigene interne expose sur des cellules tumorales apoptotiques |
CN1965082A (zh) * | 2004-02-06 | 2007-05-16 | 尼莫克斯股份有限公司 | 人源化抗体 |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
EP1786463A4 (fr) * | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | Anticorps contre le recepteur nogo |
US7504088B2 (en) | 2004-06-09 | 2009-03-17 | Kereos, Inc. | Lipophilic derivatives of chelate monoamides |
EP1778699A4 (fr) * | 2004-08-10 | 2009-02-25 | Dow Global Technologies Inc | Chelateurs et composes chelates de ciblage |
EP2301969B1 (fr) | 2005-05-06 | 2015-12-23 | ZymoGenetics, Inc. | Anticorps monoclonaux IL-31 et procédés d'utilisation |
US20080279768A1 (en) * | 2005-11-29 | 2008-11-13 | Moore Dennis A | Bifunctional Metal Chelating Conjugates |
JP2009527559A (ja) * | 2006-02-24 | 2009-07-30 | マリンクロッド・インコーポレイテッド | 二官能性レソルシノール、チオレソルシノールおよびジチオレソルシノール誘導体金属キレート形成性結合体 |
CN101400661A (zh) * | 2006-03-14 | 2009-04-01 | 马林克罗特公司 | 四氮杂大环衍生物的金属络合物 |
JP2009530294A (ja) * | 2006-03-15 | 2009-08-27 | マリンクロット インコーポレイテッド | 置換芳香族部分を有するキレート化接合体およびその誘導体 |
EP1989231B1 (fr) | 2006-03-21 | 2015-05-20 | Genentech, Inc. | Thérapie combinatoire engageant des antagonistes alpha5beta1 |
AU2007261247A1 (en) * | 2006-06-22 | 2007-12-27 | Vaccinex, Inc. | Anti-C35 antibodies for treating cancer |
EP2044090B1 (fr) | 2006-07-10 | 2015-04-08 | The Regents of The University of California | Chélate luminescent de 1-hydroxy-2-pyridinone et de lanthanides |
WO2008028192A2 (fr) | 2006-09-01 | 2008-03-06 | Zymogenetics, Inc. | Séquences de zones variables d'anticorps monoclonaux il-31, et procédés d'utilisation |
JP2010510252A (ja) * | 2006-11-21 | 2010-04-02 | バーンズ ジューイッシュ ホスピタル | キレート剤を用いるイメージング法 |
GB0624587D0 (en) * | 2006-12-08 | 2007-01-17 | Univ Muenchen Tech | Chelating agent |
US20080213780A1 (en) * | 2007-01-25 | 2008-09-04 | Lumiphore, Inc. | Multi-color time resolved fluorophores based on macrocyclic lanthanide complexes |
JP5156733B2 (ja) * | 2007-02-28 | 2013-03-06 | 国立大学法人 千葉大学 | 抗悪性腫瘍薬 |
JP2010531666A (ja) | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
ME03057B (fr) | 2007-12-07 | 2019-01-20 | Zymogenetics Inc | Molécules d'anticorps humanisés spécifiques pour l'IL-31 |
AU2008341050B2 (en) | 2007-12-26 | 2013-10-24 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
JP2009215238A (ja) * | 2008-03-11 | 2009-09-24 | Osaka Univ | 希土類発光プローブ |
CA2721093A1 (fr) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Lieurs d'albumine de serum humain, et ses conjugues |
WO2010000714A2 (fr) * | 2008-07-04 | 2010-01-07 | Oslo Universitetssykehus Hf | Kit de radio-immunoconjugué |
WO2010051544A2 (fr) * | 2008-10-31 | 2010-05-06 | Lumiphore, Inc. | Plateforme de diagnostic rapide homogène basée sur le transfert d'énergie par résonance de fluorescence des lanthanides |
SG174515A1 (en) | 2009-03-25 | 2011-10-28 | Genentech Inc | NOVEL ANTI-a5ß1 ANTIBODIES AND USES THEREOF |
WO2011025790A1 (fr) | 2009-08-24 | 2011-03-03 | Lumiphore, Inc. | Chélateurs hopo macrocycliques |
JP2013515744A (ja) * | 2009-12-24 | 2013-05-09 | ルミフォア,インコーポレイテッド | 放射性医薬品錯体 |
KR101253100B1 (ko) | 2010-02-16 | 2013-04-10 | 경북대학교 산학협력단 | 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용 |
WO2011141823A2 (fr) | 2010-05-14 | 2011-11-17 | Orega Biotech | Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17 |
US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
PL3148581T3 (pl) | 2014-05-30 | 2020-05-18 | Henlix Biotech Co., Ltd. | Przeciwciała przeciwko receptorowi naskórkowego czynnika wzrostu (EGFR) |
US10562946B2 (en) | 2014-06-20 | 2020-02-18 | Genentech, Inc. | Chagasin-based scaffold compositions, methods, and uses |
CA2956161A1 (fr) | 2014-07-23 | 2016-01-28 | Ohio State Innovation Foundation | Methodes et compositions associees a des fragments d'anticorps qui se lient a la glycoproteine 72 associee aux tumeurs (tag 72) |
GB201421162D0 (en) | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Lanthanide complex formulations |
US20180208658A1 (en) | 2015-04-03 | 2018-07-26 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
CA2980189A1 (fr) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Proteines multispecifiques de liaison a l'antigene |
ES2977137T3 (es) | 2016-09-16 | 2024-08-19 | Shanghai Henlius Biotech Inc | Anticuerpos anti-PD-1 |
US11274157B2 (en) | 2017-01-12 | 2022-03-15 | Eureka Therapeutics, Inc. | Constructs targeting histone H3 peptide/MHC complexes and uses thereof |
AU2018258049A1 (en) | 2017-04-26 | 2019-12-12 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
FR3069245B1 (fr) * | 2017-07-21 | 2019-07-26 | Guerbet | Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales |
KR20200130831A (ko) | 2018-03-14 | 2020-11-20 | 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 | 항-클라우딘 18.2 항체 |
AU2019287595A1 (en) * | 2018-04-27 | 2020-12-03 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
JP7511308B2 (ja) | 2018-06-18 | 2024-07-05 | ユーリカ セラピューティックス, インコーポレイテッド | 前立腺特異的膜抗原(psma)を標的とする構築物及びその使用 |
WO2020229974A1 (fr) * | 2019-05-10 | 2020-11-19 | Janssen Biotech, Inc. | Chélateurs macrocycliques et leurs procédés d'utilisation |
CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
EP4243935A1 (fr) * | 2020-11-10 | 2023-09-20 | Janssen Biotech, Inc. | Composés macrocycliques et leurs procédés d'utilisation |
AU2022408865A1 (en) | 2021-12-17 | 2024-07-04 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies, multispecific antibodies and methods of use |
AU2022411573A1 (en) | 2021-12-17 | 2024-06-27 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies and methods of use |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
US4454106A (en) * | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
US4472509A (en) * | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
SE8301395L (sv) * | 1983-03-15 | 1984-09-16 | Wallac Oy | Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler |
US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
US4885363A (en) * | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
EP0232751B1 (fr) * | 1986-01-23 | 1991-09-11 | E.R. Squibb & Sons, Inc. | 4,7,10-Triscarboxyméthyl-1,4,7,10-tétraazacyclododécane substitué en position 1 et analogues |
GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
DE3625417C2 (de) * | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecan-Derivate |
US5057302A (en) * | 1987-02-13 | 1991-10-15 | Abbott Laboratories | Bifunctional chelating agents |
DE3713842A1 (de) * | 1987-04-22 | 1988-11-17 | Schering Ag | Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel |
US4994560A (en) * | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
US5006643A (en) * | 1987-06-24 | 1991-04-09 | The Dow Chemical Company | Process for preparing isothiocyanato functionalized metal complexes |
GB8719041D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8719042D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
WO1989011475A1 (fr) * | 1988-05-25 | 1989-11-30 | The United States Of America, As Represented By Th | Chelates macrocycliques et leurs modes d'utilisation |
ZA894792B (en) * | 1988-06-24 | 1991-04-24 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
-
1989
- 1989-06-23 HU HU432/89A patent/HU219485B/hu unknown
- 1989-06-23 AT AT89111497T patent/ATE120457T1/de not_active IP Right Cessation
- 1989-06-23 IE IE204589A patent/IE67273B1/en not_active IP Right Cessation
- 1989-06-23 IL IL90730A patent/IL90730A0/xx unknown
- 1989-06-23 NZ NZ229700A patent/NZ229700A/xx unknown
- 1989-06-23 JP JP1508008A patent/JP2831073B2/ja not_active Expired - Lifetime
- 1989-06-23 DE DE198989111497T patent/DE353450T1/de active Pending
- 1989-06-23 EP EP89111497A patent/EP0353450B1/fr not_active Expired - Lifetime
- 1989-06-23 EP EP89908599A patent/EP0420942A1/fr not_active Withdrawn
- 1989-06-23 BR BR898907507A patent/BR8907507A/pt not_active Application Discontinuation
- 1989-06-23 WO PCT/US1989/002788 patent/WO1989012631A1/fr active IP Right Grant
- 1989-06-23 CA CA000603894A patent/CA1341373C/fr not_active Expired - Fee Related
- 1989-06-23 AU AU39794/89A patent/AU634167B2/en not_active Expired
- 1989-06-23 ES ES89111497T patent/ES2013978A4/es active Pending
- 1989-06-23 DE DE68921941T patent/DE68921941T2/de not_active Expired - Lifetime
-
1990
- 1990-02-23 KR KR90700403A patent/KR0137930B1/ko not_active IP Right Cessation
- 1990-02-23 NO NO900869A patent/NO179008C/no not_active IP Right Cessation
- 1990-02-23 DK DK199000493A patent/DK175393B1/da not_active IP Right Cessation
- 1990-12-21 FI FI906368A patent/FI103792B1/fi active IP Right Grant
-
1991
- 1991-07-31 GR GR90300034T patent/GR900300034T1/el unknown
-
1992
- 1992-10-15 US US07/962,168 patent/US5435990A/en not_active Expired - Lifetime
-
1996
- 1996-04-11 HK HK60696A patent/HK60696A/xx not_active IP Right Cessation
-
1998
- 1998-10-23 FI FI982303A patent/FI117889B/fi active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ229700A (en) | Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments | |
AU7366687A (en) | Coupling agents for radiolabeling proteins | |
NO304552B1 (no) | Kompleksforbindelser, konjugater, farmas°ytiske preparater inneholdende slike og forbindelser | |
ATE178597T1 (de) | Biologisch nützliche konjugate | |
HU911929D0 (en) | Process for the production of conjugates containing orto ligating functional group from chelate complexes and joint antibodies or antibody fragments and the medical preparations containing thereof | |
EP0341304A4 (en) | Improved ricin molecules and ricin toxin conjugates | |
GR3026575T3 (en) | Conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) |